Primary cutaneous CD30 (Ki-1)-positive non-anaplastic B-cell lymphoma.
BACKGROUND
The CD30 (Ki-1)-positive lymphoproliferative disorders show a non-epidermotropic infiltrate of large-sized pleomorphic T cells, being extremely rare those that develop from B cells.


METHODS
A 51-year-old white man presented with a 8x10 cm lobulated scalp tumor that had developed during the previous 8 months. Histopathology demonstrated a proliferation of medium and large-sized non-anaplasic lymphocytes. The tumor cells (CD45+) expressed B phenotype (CD20+, CD3) and were CD30 (Ki-1) positive. The extension study revealed no extracutaneous involvement and the lesion resolved following chemotherapy. Two years later, after six cycles of chemotherapy that followed the CHOP protocol the patient remained asymptomatic.


CONCLUSIONS
We report a patient with a diffuse lymphoma of medium and large-sized B phenotype cells on the scalp that showed the unusual characteristic of being both non-anaplastic and CD30 (Ki-1) positive.
Herrera
Enrique
E
Department of Dermatology, University Hospital, School of Medicine, Málaga, Spain. dermafac@ccuma.sci.uma.es
Gallardo
María
M
Bosch
Ricardo
R
Cabra
Blanca
B
Aneri
Vicente
V
Sánchez
Purificación
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage; D015328:Gene Rearrangement, B-Lymphocyte, Light Chain / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000008:administration & dosage; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D017730:Ki-1 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone